림프종 · CD19

116개 · ADC 890 · Antibody 4097 · CGT 2985 · 다음 갱신 D-6 · 마지막 9월 2일

PopularRecently updatedCuratedMost trialsNeeds refreshORRLatestPhase 3FDA approved116 programs
CGTCurated CoreFDANovartisApproved

tisagenlecleucel (Kymriah, tisa-cel)

ALL, DLBCL, FL · CD19

#CD19#CGT#Approved#FDA-approved#BioJungboMoa-pick+5
Trials 48Status Approved
CGTStandard DatabasestaleAstraZenecaPhase 2

autologous CD19-directed chimeric antigen receptor (CAR, autologous CD19-directed chimeric antigen receptor, autologous CD19-directed chimeric antigen receptor (CAR) T-cells)

Relapsed Non Hodgkin Lymphoma; Relapsed Adult ALL · CD19

#CD19#CGT#Phase2#Popular#cell-gene-therapy+5
Trials 154Status Recruiting
CGTStandard DatabasestaleBioceltech Therapeutics, Ltd.Phase 2

CD19 CAR T cells (CD19 CAR T cells)

Lymphomas Non-Hodgkin's B-Cell; Relapse · CD19

#CD19#CGT#Phase2#Popular#cell-gene-therapy+5
Trials 128Status Recruiting
CGTLimited DatastaleJuventas Cell Therapy Ltd.Phase 1

CD19 CAR-T (CD19 CAR-T)

B-cell Malignancy; B-cell Lymphoma · CD19

#CD19#CGT#Phase1#Popular#cell-gene-therapy+5
Trials 93Status Active
CGTStandard DatabasestaleShanghai Ming Ju Biotechnology …Phase 2

CD19-targeted Chimeric Antigen Receptor (CAR, CD19-targeted Chimeric Antigen Receptor, CD19-targeted Chimeric Antigen Receptor (CAR) T Cells)

Lymphoma, Non-Hodgkin; Diffuse Large B Cell Lymphoma · CD19

#CD19#CGT#Phase2#Popular#cell-gene-therapy+5
Trials 64Status Active
CGTLimited DatastaleSinobioway Cell Therapy Co., Lt…Preclinical

CD19-targeted CAR-T cells (CD19-targeted CAR-T cells)

Lymphoma · CD19

#CD19#CGT#Preclinical#Popular#cell-gene-therapy+5
Trials 60Status Active
CGTStandard DatabasestaleAbClonPhase 2

Anti-CD19 Chimeric Antigen Receptor T cell (AT101, AT101(Anti-CD19 Chimeric Antigen Receptor T cell))

B-cell Non Hodgkin Lymphoma · CD19

#CD19#CGT#Phase2#Popular#cell-gene-therapy+5
Trials 59Status Recruiting
CGTLimited DatastaleNational Taiwan University Hosp…Phase 1

CD19 Chimeric Antigen Receptor (CAR, CD19 Chimeric Antigen Receptor, CD19 Chimeric Antigen Receptor (CAR) T Cells)

Relapsed/Refractory B-Cell Malignancies · CD19

#CD19#CGT#Phase1#Popular#cell-gene-therapy+5
Trials 56Status Active
CGTStandard DatabasestaleNational Cancer Institute (NCI)Phase 2

Anti-cluster of differentiation 19 (CD19, Anti-cluster of differentiation 19, Anti-cluster of differentiation 19 (CD19)-CAR PBL)

Primary Mediastinal B-cell Lymphoma; Diffuse, Large B-cell Lymphoma · CD19

#CD19#CGT#Phase2#Popular#cell-gene-therapy+5
Trials 55Status Active
CGTLimited DatastaleNational Cancer Institute (NCI)Phase 1

Anti-cluster of differentiation 19 (CD19, Anti-cluster of differentiation 19, Anti-cluster of differentiation 19 (CD19)-Chimeric Antigen Receptor (CAR) T cells)

Lymphoma, B-Cell; Lymphoma, Non-hodgkins · CD19

#CD19#CGT#Phase1#Popular#cell-gene-therapy+5
Trials 55Status Active
CGTLimited DatastaleHebei Senlang Biotechnology Inc…Preclinical

CD19+CD22 CAR-T (CD19+CD22 CAR-T)

Relapsed or Refractory B-cell Non-Hodgkin Lymphoma · CD19

#CD19#CGT#Preclinical#Popular#cell-gene-therapy+5
Trials 53Status Active
CGTLimited DatastaleCRISPR Therapeutics AGPhase 1

CD19-directed CAR-T cells (CD19-directed CAR-T cells)

B-cell Non-Hodgkin Lymphoma · CD19

#CD19#CGT#Phase1#Popular#cell-gene-therapy+5
Trials 53Status Active
ADCStandard DatabasestaleADC TherapeuticsPhase 2

Anti-CD19 Antibody-Drug Conjugate (Loncastuximab Tesirine, Loncastuximab Tesirine (Anti-CD19 Antibody-Drug Conjugate))

Diffuse Large B-Cell Lymphoma; High-grade B-cell Lymphoma (HGBCL) · CD19

#CD19#ADC#Phase2#antibody-drug-conjugate#DiffuseLargeB-CellLymphoma+2
Trials 48Status Recruiting
CGTLimited Datastalejiuwei cuiPhase 1

CD19-targeted CART cells (CD19-targeted CART cells)

Leukemia, B-Cell · CD19

#CD19#CGT#Phase1#cell-gene-therapy#CAR-T+5
Trials 39Status Active
CGTStandard DatabasestaleMinsk Scientific-Practical Cent…Phase 2

CD19+22 CAR-T cells (CD19+22 CAR-T cells)

Acute Lymphobkastic Leukemia; B Cell Lymphoma · CD19

#CD19#CGT#Phase2#cell-gene-therapy#CAR-T+5
Trials 33Status Recruiting
CGTLimited DatastaleRui Therapeutics Co., LtdPhase 1

anti-CD19 CAR-NK cells (anti-CD19 CAR-NK cells)

Refractory/Recurrent Central Nervous System Lymphoma · CD19

#CD19#CGT#Phase1#cell-gene-therapy#CAR-T+5
Trials 32Status Active
CGTLimited DatastaleChinese PLA General HospitalPhase 2

Anti-BCMA-CD19 CAR-T cells (Anti-BCMA-CD19 CAR-T cells)

IgG4 Related Disease; B-cell Mediated Autoimmune Disorders · CD19

#CD19#CGT#Phase2#cell-gene-therapy#CAR-T+5
Trials 30Status Recruiting
CGTLimited DatastaleInstituto de Investigación Hosp…Phase 1

Autologous CD19/CD22 CAR T cells (Autologous CD19/CD22 CAR T cells)

Precursor Cell Lymphoblastic Leukemia-Lymphoma · CD19

#CD19#CGT#Phase1#cell-gene-therapy#CAR-T+3
Trials 30Status Recruiting
CGTStandard DatabasestaleYake Biotechnology Ltd.Phase 2

CAR-T cells targeting CD19 and CD22 (CAR-T cells targeting CD19 and CD22)

B-Cell Acute Lymphoblastic Leukemia, Adult · CD19

#CD19#CGT#Phase2#cell-gene-therapy#CAR-T+4
Trials 30Status Active
CGTStandard DatabasestaleKara Yakhteh Tajhiz Azma CompanyPhase 2

anti-CD19 CAR T cell therapy (anti-CD19 CAR T cell therapy)

Relapse/Refractory B-cell Acute Lymphoblastic Leukemia · CD19

#CD19#CGT#Phase2#cell-gene-therapy#CAR-T+4
Trials 30Status Recruiting

1 / 6 pages

← PreviousNext →